[Short-term effects with sucroferric oxyhydroxide in hemodialysis patients: Experience in NephroCare France].

Affiliation

NephroCare France, 47, avenue des Pépinières, 94260 Fresnes, France. Electronic address: [Email]

Abstract

BACKGROUND : Despite a better management of hyperphosphatemia in haemodialysis patients observed during the past years, most of them remain insufficiently treated and exposed to bone and cardiovascular complications that are associated with this biological abnormality. The availability of calcium-free phosphate binders among therapeutical options is confirmed to significantly reduce serum phosphate levels without the risk of excess exposure to calcium. Currently sucroferric oxyhydroxyde (SO) is the only iron-based phosphate binder available in France.
METHODS : A cohort of patients prescribed OHS has been extracted from the EUCLID 5 database between June 2016 and December 2017. The effects on bone mineral metabolism and ferritin have been retrospectively studied.
RESULTS : Two hundred and sixty-two patients with OHS prescription have been identified. The OHS treatment duration median was 4.3 months (1.84-10.99). The average midweek phosphatemia decreased significantly after OHS prescription (from 1.99 to 1.83 mmol/L ; P<0.0001) with a significant increase of the proportion of patients (12.1 to 25.7% ; P<0.0001) reaching the phosphate target of 1.5 mmol/L, without significant change in calcemia and PTH. Ferritinemia significantly increased from 362 to 427 μg/L in 3 months (P=0.0049). OHS therapy has been stopped and replaced in 18% of the cases.
CONCLUSIONS : Among the NephroCare cohort, OHS therapy was efficient to decrease phosphatemia and to increase significantly the proportion of patients in target. There were no short term changes in calcemia and PTH. The slight increase in ferritin confirms the findings of the phase III study and its extension. The effects on the pills count and the OHS side-effects are analyzed from literature. The risk of iron overload and the impact on the anemia management including EPO sparing are currently under study.
CONCLUSIONS : OHS therapy appears to be a new efficient alternative to non-calcium phosphate binders. A better knowledge of its side effects will help the patients and the physician to optimize the phosphate balance management. The slight increase in ferritin can be considered as an epiphenomenon because of the important iron needs and frequent check of this parameter in the anemia management.

Keywords

Calcium-free phosphate binder,Chélateur du phosphate non calcique,Dialyse,Dialysis,Données en vie réelle,Hyperphosphatemia,Hyperphosphatémie,Oxyhydroxyde sucroferrique,Real-world evidence,Sucroferric oxyhydroxyde,